- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024kr230.2 (-0.78%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024kr217.2 (+8.17%)Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023kr213 (-1.75%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023kr291.4 (+0.48%)Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023kr254 (+8.55%)Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023kr297.4 (-1.78%)Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022kr250 (+4.60%)Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022kr78.35 (-3.15%)Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022kr74.3 (-6.54%)Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022kr110.2 (-1.25%)Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021kr143.8 (-1.64%)Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021kr145.2 (+4.91%)Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021kr92.6 (+2.66%)Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021kr99.8 (-0.70%)Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020kr88.45 (+1.43%)Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020kr80.55 (+7.69%)Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020kr64.4 (-7.07%)Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020kr82.65 (-3.22%)Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019kr92.5 (+1.82%)Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019kr71.7 (-0.42%)Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019kr75.5 (+0.47%)Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019kr97.75 (+2.79%)Earnings
Q2 2021 BioArctic AB Earnings Call Transcript
Welcome to the BioArctic Q2 Report 2021. Today, I am pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. (Operator Instructions) Speakers, please begin.
()-
Thank you so much. Most welcome to BioArctic's Second Quarter Report for 2021. I'm Gunilla Osswald, and I'm the CEO of BioArctic and I will share the presentation here today with our CFO, Jan Mattsson.
I think it's exciting times for the Alzheimer's community now, both regarding diagnostics with progress of blood biomarkers and also with new therapies. We are most likely on our way towards a paradigm shift for the treatment of Alzheimer's disease. And our most advanced program, lecanemab, previously called BAN2401, was granted breakthrough therapy designation by the FDA in late June. And I will describe more about that in the presentation here today.
Next slide, please. BioArctic is listed on Nasdaq Stockholm Mid-Cap, and this is our disclaimer.
Next slide, please. BioArctic is a unique Swedish
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)